This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
With All India Institute of Ayurveda as a knowledge partner and Sodexo’s culinary expertise, Aarogyum is a well-rounded offering in patient dining solutions
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Nous-209 has been developed using the Nouscom's viral vector platform
Subscribe To Our Newsletter & Stay Updated
